NCT00822692

Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection

Prospective Randomized Double Blind, Placebo-Controlled Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection on 30 Day Recurrence Rates.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 139 (actual)
• Sponsor: 59th Medical Wing · Federal
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Patients will be enrolled in a multi-center study (Wilford Hall Medical Center and Brooke Army Medical Center) to prospectively evaluate outcome after treatment for an uncomplicated skin abscess.

Detailed description

All patients will receive incision and drainage and wound cultures. Patients will then be randomized to 1) septa double strength two pills orally twice a day x 7 days or 2)placebo. Patients will then return to the emergency room on days 3 and 7 for wound repacking and evaluation. The primary outcome recurrence rates within 30 days of treatment. Patients who are not improving at the following visit will then be treated with additional antibiotics if needed. Data will be analyzed both by initial randomization and intention to treat.

Conditions

• Abscess
• Methicillin-Resistant Staphylococcus Aureus Infection

Interventions

Type	Name	Description
DRUG	Trim/ Sulfa DS	bactrim DS (800/160) two tablets PO BID x 7 days
DRUG	placebo	matched placebo 2 pills PO BID x 7 days

Timeline

• Start date: 2008-07-01
• Primary completion: 2009-06-01
• Completion: 2009-06-01
• First posted: 2009-01-14
• Last updated: 2015-12-21
• Results posted: 2009-09-03

Locations

1 site across 1 country: United States